Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

GRI-0621

Alternative Names: gri-0621, gri0621, gri 0621
Clinical Status: Active
Latest Update: 2025-05-22
Latest Update Note: News Article

Product Description

GRI Bio was developing gri-0621, an oral NKT Inhibitor for Patients With Chronic Liver Disease. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02949375)

Mechanisms of Action: NKT Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GRI Bio
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GRI-0621

Countries in Clinic: Australia, United Kingdom, United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - GRI Bio presented P0 Inflammation|Pulmonary Fibrosis|Autoimmune Disease Unspecified results on 2025-05-21 for GRI-0621
  • Clinical Outcomes Expected - GRI Bio announced they will present P2 Idiopathic Pulmonary Fibrosis results in 3Q25 for GRI-0621
  • Clinical Outcomes Reported - GRI Bio presented P2 Idiopathic Pulmonary Fibrosis results on 2025-05-08 for GRI-0621

Highest Development Phases

Phase 2: Idiopathic Pulmonary Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
GRI-0621-IPF-02

P2

Recruiting

Idiopathic Pulmonary Fibrosis

2025-06-01

12%

2025-03-08

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title

05/22/2025

News Article

 GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

05/21/2025

News Article

 GRI Bio to Participate in the Virtual Investor Closing Bell Series

05/16/2025

News Article

 GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

05/15/2025

News Article

 GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions